These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 26996268

  • 21. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL).
    Baker E, Harris WT, Guimbellot JS, Bliton K, Rowe SM, Raju SV, Oates GR.
    J Cyst Fibros; 2024 Sep; 23(5):959-966. PubMed ID: 39033068
    [Abstract] [Full Text] [Related]

  • 22. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M, KIWI Study Group.
    Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
    [Abstract] [Full Text] [Related]

  • 23. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
    Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS.
    J Cyst Fibros; 2018 Jan; 17(1):83-88. PubMed ID: 28651844
    [Abstract] [Full Text] [Related]

  • 24. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D.
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [Abstract] [Full Text] [Related]

  • 25. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
    Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G, VX15-661-113 Investigator Group.
    J Cyst Fibros; 2019 Sep; 18(5):708-713. PubMed ID: 31253540
    [Abstract] [Full Text] [Related]

  • 26. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.
    Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM, VX11-770-901 investigators.
    J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022
    [Abstract] [Full Text] [Related]

  • 27. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
    Abou Alaiwa MH, Launspach JL, Grogan B, Carter S, Zabner J, Stoltz DA, Singh PK, McKone EF, Welsh MJ.
    JCI Insight; 2018 Aug 09; 3(15):. PubMed ID: 30089726
    [Abstract] [Full Text] [Related]

  • 28. Cystic fibrosis with non-G551D gating mutations in Italy: Epidemiology and clinical characteristics.
    Salvatore D, Carnovale V, Majo F, Padoan R, Salvatore M, Taruscio D, Amato A, Ferrari G, Campagna G.
    Pediatr Pulmonol; 2021 Feb 09; 56(2):442-449. PubMed ID: 33219628
    [Abstract] [Full Text] [Related]

  • 29. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor.
    Mesbahi M, Shteinberg M, Wilschanski M, Hatton A, Nguyen-Khoa T, Friedman H, Cohen M, Escabasse V, Le Bourgeois M, Lucidi V, Sermet-Gaudelus I, Bassinet L, Livnat G.
    J Cyst Fibros; 2017 Jan 09; 16(1):45-48. PubMed ID: 27659740
    [Abstract] [Full Text] [Related]

  • 30. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults.
    Kim J, Farahmand M, Dunn C, Milla CE, Horii RI, Thomas EAC, Moss RB, Wine JJ.
    Sci Rep; 2018 Nov 02; 8(1):16233. PubMed ID: 30389955
    [Abstract] [Full Text] [Related]

  • 31. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ, Murphy DM, Plant BJ.
    N Engl J Med; 2013 Sep 26; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract] [Full Text] [Related]

  • 32. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
    Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N.
    J Cyst Fibros; 2021 Nov 26; 20(6):965-971. PubMed ID: 33573995
    [Abstract] [Full Text] [Related]

  • 33. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N.
    McGarry ME, Nielson DW.
    Chest; 2013 Oct 26; 144(4):e1-e4. PubMed ID: 24081349
    [Abstract] [Full Text] [Related]

  • 34. Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Barry PJ, Jones AM, Webb AK, Horsley AR.
    Thorax; 2014 Jun 26; 69(6):586-7. PubMed ID: 24258833
    [Abstract] [Full Text] [Related]

  • 35. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F.
    Lancet Respir Med; 2013 Oct 26; 1(8):630-638. PubMed ID: 24461666
    [Abstract] [Full Text] [Related]

  • 36. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.
    Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A.
    J Cyst Fibros; 2016 Jan 26; 15(1):67-73. PubMed ID: 25769931
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, Higgins M.
    J Cyst Fibros; 2014 Dec 26; 13(6):674-80. PubMed ID: 25266159
    [Abstract] [Full Text] [Related]

  • 38. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
    Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC, KLIMB study group.
    J Cyst Fibros; 2019 Nov 26; 18(6):838-843. PubMed ID: 31053538
    [Abstract] [Full Text] [Related]

  • 39. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D.
    Clin Otolaryngol; 2015 Feb 26; 40(1):16-21. PubMed ID: 25145599
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.